Mapping phlpp-driven mechanisms of pain and pathogenesis in post-traumatic osteoarthritis

Active Grant Awarded

Award ID
K99AR086961
Recipient
Awarding agency
Obligated
$211,196

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 10% complete
Funding agency
National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
Place of performance
Rochester, MN 55905, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through its National Institute of Neurological Disorders and Stroke, awarded Mayo Clinic $211,196 on September 9, 2026, under Drug Use and Addiction Research Programs (CFDA 93.279), grant number K99AR086961. The award funds a research project examining how inhibiting PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) reduces pain behaviors in post-traumatic osteoarthritis. Aim 1 quantifies neurite innervation and vascular sprouting in Nav1.8;tdTomato reporter mice and applies high-resolution spatial transcriptomics to knee joints at early and late post-traumatic osteoarthritis stages to map signaling changes linked to pain behaviors and subchondral bone innervation. Aim 2 conditionally deletes PHLPP1 in osteoclasts during DMM-induced post-traumatic osteoarthritis and measures pain behaviors, cartilage damage, and molecular changes in injured joints. The period of performance runs from the September 9, 2026 award date to an ultimate completion date of August 31, 2028. Work is performed in Rochester, Minnesota (55905). The source identifies no sub-recipients on this award.

Description

Abstract
Post-traumatic osteoarthritis (PTOA) is a common, progressive and debilitating disease that poses a major socio- economic burden in the US. No disease-modifying medications exist despite persistent pain in nearly half of patients and surgical risks. PTOA is characterized by pathological changes in many joint tissues. Articular cartilage deterioration, subchondral bone sclerosis, and sensory nerve innervation can cause joint stiffness and pain. PH domain leucine-rich repeat protein phosphatases (PHLPPS) are suppressors of chondrocyte regeneration and pain-related behaviors. Intra-articular injection of phlpp inhibitors (PHLPPI) or deletion of PHLPP1 prevents joint hypersensitivity and cartilage degradation in a model of PTOA. Preliminary data show that phlpp inhibition suppresses outgrowth of small/medium sensory neurons and expression of neurotransmitters and neurofilaments in vitro as well as subchondral bone innervation in vivo in mice. The research proposed under this training period will explore how PHLPP1 inhibition reduces PTOA-associated pain behaviors. The long- term goal is to define mechanisms by which PHLPP1 contributes to OA pain, guiding the development of targeted pain-relief strategies. My central hypothesis is that PHLPP1 promotes OA pain by altering signaling cascades in pain-producing cells during OA progression. In aim 1, I will assess how PHLPP1 loss prevents joint pain by quantifying neurite innervation and vascular sprouting using NAV1.8; tdtomato reporter mice and by applying high-resolution spatial transcriptomics of knee joints at early and late PTOA stages to map downstream signaling changes linked to pain behaviors and subchondral bone innervation. In aim 2, I will conditionally delete PHLPP1 in osteoclasts during DMM-induced PTOA and measure pain behaviors, cartilage damage, and molecular changes in injured joints. The research training, career development, and mentorship plan outlined here will support my goal of becoming an independent investigator in musculoskeletal pain research. During the K99 phase, I will receive primary mentorship from DR. Jennifer westendorf and complementary expertise from advisory committee members in pain neuroscience, osteoclast biology, advanced imaging, and spatial transcriptomics. Additional CO-mentorship from DR. Susan moeschler, a clinical pain expert, will strengthen the translational relevance of my work. Structured training in grant writing, communication, leadership, and mentoring will support my transition to independence during the R00 phase. The mayo clinic offers an exceptional environment with extensive institutional resources in musculoskeletal biology, imaging, spatial transcriptomics, behavioral phenotyping, computational analysis, and translational research. Together, this environment and mentoring team will provide the interdisciplinary training and support needed to achieve my career goals.

Quick answers

Who received award K99AR086961?

K99AR086961 was awarded to Mayo Clinic by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 9, 2026.

How much is award K99AR086961 worth?

$211,196 has been obligated on K99AR086961.

Which agency awarded K99AR086961?

National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) awarded K99AR086961, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award